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Abstract
Heart failure is a global public health challenge frequently presenting to the emergency 
department. After initial stabilization and management, one of the most important decisions is to 
determine which patients can be safely discharged and which require hospitalization. This is a 
complex decision that depends on numerous subjective factors, including both the severity of the 
patient’s underlying condition and an estimate of the acuity of the presentation. An emergency 
department observation period may help select the correct option. Ideally, during an observation 
period, risk stratification should be carried out using parameters specifically designed for use in 
the emergency department. Unfortunately, there is little objective literature to guide this 
disposition decision. An objective and reliable definition of low-risk characteristics to identify 
early discharge candidates is needed. Benchmarking outcomes in patients discharged from the 
emergency department without hospitalization could aid this process. Biomarker determinations, 
although undoubtedly useful in establishing diagnosis and predicting longer-term prognosis, 
require prospective validation for emergency department disposition guidance. The challenge of 
identifying emergency department acute heart failure discharge candidates will only be overcome 
by future multidisciplinary research defining the current knowledge gaps and identifying potential 
solutions.
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Introduction
Heart failure is a global public health challenge, with as many as 15 million Europeans and 
5.7 million US citizens living with this diagnosis.1–3 It is characterized by frequent 
hospitalizations, estimated to exceed one million annual admissions in each of Europe and 
the USA, and accounts for the majority of the yearly costs of heart failure-related care.4,5 A 
recent Spanish study estimated costs of €10,771 per patient during a two-year follow-up 
period,6 and total system costs in the USA are estimated to increase from US$31bn in 2012 
to US$70bn in 2030.5 Ultimately, successful strategies to safely avoid hospitalization could 
have a major impact, not only on the quality of life for heart failure patients, but also on 
societal costs.
Miró et al. Page 2
Eur Heart J Acute Cardiovasc Care. Author manuscript; available in PMC 2018 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The role of emergency departments in heart failure
Shortness of breath, one of the most frequent complaints in patients presenting with acute 
heart failure (AHF), has a wide differential diagnosis and is one of the most common of 
emergency department (ED) presentations. Since as many as 80% of AHF patients are 
hospitalized through the ED, emergency physicians play a central role in the determination 
of AHF treatment and disposition.
The classical combination of clinical history, physical examination, electrocardiogram, chest 
X-ray and laboratory analysis (including a natriuretic peptide) allow emergency physicians 
to reliably diagnose the majority of AHF patients.7,8 Recently available tools to evaluate 
patients complaining of dyspnoea, such as computed tomography scanning, bedside 
echocardiography, and lung ultrasound, can add useful information. Early diagnosis is 
necessary to initiate treatment as soon as possible, since rapid therapeutic intervention 
favourably impacts both patient outcome and hospital length of stay.9
Identification of the precipitant of decompensation is important as this may contribute in the 
disposition decision. For example, while dietary indiscretion may be easily treated by a 
temporary increase in diuretics and ED discharge, a concomitant acute coronary syndrome, 
pulmonary infection or arrhythmia will need hospital admission. In fact, it has been reported 
that in more than 50% of AHF episodes, at least one of these precipitants is present.10,11 All 
these conditions must be investigated and treated early during the ED evaluation, and in 
parallel with specific AHF treatment.
Once an AHF diagnosis is made and treatment started, several disposition options regarding 
the ultimate placement of the patient should be considered. These include into the intensive 
care unit, a general hospital ward, or discharge home, with or without a short period of 
supervision of treatment response in an ED-dependent observation unit. In this sense, 
disposition decision-making is unique to the ED and crucial. After initial stabilization and 
management, one of the most important ED considerations is to determine which patients 
need to be hospitalized for further treatment and/or studies and which can be safely 
discharged to the community. Unnecessary hospital admissions are linked to unacceptable 
costs increases, while inappropriate ED discharges put the patient at increased risk of 
adverse outcomes. In this scenario, and especially as no clear consensus guiding such a 
decision-making exists, emergency physicians tend to act conservatively. This is because, 
after a discharge decision, there is no second opinion, no ability to evaluate treatment 
response and no capability to intervene in a less than optimal social situation. In this setting, 
a wrong ‘discharge-home’ decision may actually harm the patient and discharges without 
due consideration are also a potential litigation risk. It is because of this environment that the 
overwhelming majority of heart failure patients presenting to the ED are hospitalized.
The variability of emergency departments and emergency medicine 
worldwide
Large ED infrastructure and acute cardiac care/emergency medicine practice variations exist. 
For example, because the response to AHF treatment is not immediate, an observation 
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period after initial therapy is useful to help define the correct disposition. Unfortunately, this 
timeframe (usually 12–24 h) is simply not available in all EDs. Further, even when 
observation options are available, global standardization has been challenging as ED 
organization and staffing, cardiologist involvement, provider credentials, ED capabilities and 
patient care pathways are highly variable.12,13 Good practices should include well-defined 
local guidelines, treatment protocols, admission criteria and referral pathways. These factors 
may be missing in some EDs.14 Finally, cardiologists must play a central role in the 
provision of care to AHF patients. However, because cardiologist involvement in ED 
disposition-decisions is also diverse, opportunities for improvement may exist in some 
institutions.
Observation units linked to the ED are used in some hospitals and countries, but are highly 
variable according to their characteristics and the specialists in charge.15–17 For AHF, the 
observation unit may represent a good destination for the less sick patient to check clinical 
improvement, obtain cardiologist advice, receive proper education and instruction and have 
their post-discharge appointments arranged, thereby allowing direct discharge without 
hospitalization. Where available, pre-discharge assessment by the heart failure team and 
patient linkage with the heart failure clinic is desirable. In the absence of an observation 
option, admission of practically all patients with AHF will be the rule.
It is important to note that an observation unit strategy is consistent with the current trend in 
health care management, developed during the last decade, of avoiding unnecessary hospital 
admissions by creating health care structures, resources and pathways to support ambulatory 
care for patients that otherwise would have been hospitalized. The main goals behind the 
transition to outpatient management are to reduce costs, prevent hospital-related 
complications and readmissions and provide health care in the patient’s usual 
environment.18–20
Direct ED discharge of AHF patients: realities and uncertainties
Considering global ED variability, and that AHF may manifest from minor decompensation 
to life-threatening illness, it is easy to understand the worldwide variation in the proportion 
of AHF patients considered for direct ED discharge. Direct ED discharge will seldom occur 
in EDs unable to provide a post-treatment observation period, nor will it be common in those 
EDs without immediate availability of bedside echocardiography, rapid natriuretic peptide 
measurement or outpatient cardiology/heart failure clinic referral. Conversely, direct 
discharge may be considered in most AHF patients admitted to an observation unit. The 
presence of an observation strategy may explain some of the large differences in direct ED 
discharge of AHF found among countries, but what is the right proportion of patients who 
can be safely discharged home from the ED has not been established. While in the USA only 
16% of patients are directly discharged from the ED,21 this figure rises to 24% in Spain22 
and 36% in Canada.23
Not all practitioners agree with an ED discharge strategy. The usual high level of ED activity 
and occupancy, with overcrowding during certain hours of the day or periods of the year, 
together with the lack of inpatient beds in many hospitals worldwide, may put ED 
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physicians under excessive pressure to discharge patients who, in other circumstances, 
would be admitted.24,25 It has been shown that across countries and across US hospitals, 
longer median length of stay of patients admitted for heart failure was independently 
associated with lower risk of readmission.26 Additionally, Lee et al. have shown that, in 
patients with comparable predicted risks of death, subsequent 90-day mortality rates were 
higher among discharged (11.9%) than admitted (9.5%) patients.27
Adverse events must be accounted for within the system in which they occur. In some cases, 
adverse events are not related to a wrong discharge decision and may be related to failure of 
proper post-discharge follow-up. Interestingly, when AHF patients directly discharged from 
ED were asked about their opinion on the ED disposition-decision, more than 90% agreed 
with going home.28 Additionally, there is no difference in the ED subjective quality scores 
given by the patients directly discharged from ED as compared with those hospitalized, nor 
are these scores influenced by post-discharge adverse events, which seems to indicate that 
AHF patients directly discharged from ED do not blame emergency physicians for their ED 
return visits.28 Nonetheless, ‘Is direct discharge safe?’ ‘How should we measure success or 
failure?’ and ‘What are acceptable rates for short-term ED re-visits, hospital admissions, or 
even death, after direct ED discharge?’ are questions that still need to be addressed.29
It is quite reasonable to think that EDs discharging a very small proportion of AHF patients 
will achieve a lower rate of adverse events than those discharging a higher proportion 
because the former are selecting the least sick, for whom better outcomes are foreseeable. 
Figure 1, comparing the rates of ED discharge versus adverse events, seems to support such 
a direct relationship. However, no understanding of the intensity of care pathways is 
provided by these data. Additionally, it is difficult to attribute an adverse event to wrong ED 
discharge decision-making, with any certainty, because AHF is a syndrome with an 
inherently high morbidity and mortality. For example, patients with advanced heart failure 
may have a high basal risk of death and readmission, but even early discharge can be 
considered appropriate in some instances. This speaks to the need of randomized control 
groups in all discharge studies, so that the impact of early discharge can be evaluated. Even 
after inpatient hospitalization, the rates of re-hospitalization or death during the following 30 
days are markedly higher than for other conditions and are consistently reported to be near 
30% and 10%, respectively.22,23,30–32 Of course, it is anticipated that hospitalized patients 
represent a cohort with greater severity of illness, but if a subset with one-third of patients 
with low-risk of adverse events can be identified, would not both patients and health care 
systems benefit from hospitalization avoidance?
While there are few studies comparing AHF outcomes based on disposition (discharge/
hospitalization), or the practitioner who is discharging them (hospitalists/ED physician), 
there are analyses documenting that standardizing observation care and the implementation 
of treatment protocols is associated with markedly lower rates of rehospitalization. In fact, in 
one ‘before and after’ outcome study of 154 patients following implementation of an AHF 
observation unit treatment protocol, the overall 90-day heart failure revisit rate decreased by 
43%, and the death rate, initially 4%, declined to 1%.33 These authors suggested that to 
obtain optimal outcomes it may not be sufficient to simply provide an observation option for 
emergency physicians and that it may be necessary to provide proper infrastructure to 
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maximize downstream benefits. Furthermore, because results commented on above were 
obtained by the application of published observation unit inclusion, exclusion and discharge 
criteria, implementation of such criteria may also be important for the successful 
management of the early discharge candidate.34,35 Finally, it is important to emphasize that 
all these discharge plans have to be developed using a multidisciplinary approach, in 
conjunction with cardiologists and heart failure clinics and teams, in order to provide the 
best assessment and options to the patient.
The challenge to define low-risk patients
Despite efforts to identify a risk stratification strategy that selects patients at low risk, an 
important question remains: how do we define low risk? This has to be answered from the 
perspective of an ED physician and must describe what is the appropriate threshold defining 
a particular patient as low risk. In an attempt to cover this gap, a recent expert consensus 
document proposes standards for adverse outcomes in AHF patients directly discharged 
from the ED.36 These authors propose that in EDs with observation units, the discharge rate 
should be above 40%, and the 30-day ED/hospital readmission, and mortality rates should 
be below 20% and 2%, respectively. For institutions without observation units available, 
these rates were recommended to be above 20%, and below 15% and 1%, respectively. The 
lower rates proposed for the EDs without observation capabilities are justified by the fact 
that they are discharging fewer patients and thus selecting only those at lowest risk. These 
figures are arbitrary, with a level of evidence of C, yet they are aimed to challenge EDs to 
improve outcomes and system resource use. Local audit and benchmarking is essential, with 
stakeholder involvement in identifying problems, designing solutions and re-auditing the 
impact of any changes.
Finally, ED discharge does not have to lead to an increase in patient risk. However, when ED 
discharge is performed, ED physicians must assure that even though the patient is at low 
risk, a minimum number of clinical precautions should be enacted before discharging, 
including factors that encourage successful patient self-management.37 These include the 
presence of partner or care-giver, an appropriate supply of medication, arrangement of 
follow-up visits (either at home by nurse or primary care physician, or at a clinic, primary 
care or hospital) and specific advice given about when to seek further help or return to the 
ED. Patients’ follow-up by either heart failure clinic, general cardiologist or internist should 
be mandatory. In addition to risk stratification to identify low-risk patients, barriers to 
successful outpatient management should be evaluated. In institutions capable of providing 
prolonged observation, this may be the ideal environment to identify challenges and initiate 
strategies to overcome their impact. However, when selfcare barriers are perceived which are 
not possible to overcome during an ED stay, hospitalization is required, even in those 
otherwise rated as low risk. Finally, for patients experiencing their first episode of heart 
failure, hospital admission for further investigations is mandatory.
Risk stratification of AHF patients
In our current scenario, it is crucial to perform ED AHF risk stratification. The aim of such 
stratification is to allow a rational and objective decision regarding a patient’s final 
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disposition. In general, criteria for identifying patients who are at increased risk of adverse 
events and who may benefit from hospitalization are better delineated than those variables 
characterizing patients safe for ED discharge.38 In fact, the objective identification of low-
risk AHF patients remains a challenge.
One attractive strategy to identify early discharge candidates is to include only those patients 
without any of the significant risk factors described as influencing outcome (Table 1).39 
Unfortunately, the absence of high risk does not equate to the presence of low risk, and a 
specific tool identifying low-risk AHF patients could help improve ED decision-making. 
Some authors have proposed risk stratification scales to separate highest and lowest risk 
patients, so that the former can be hospitalized and the latter considered as discharge 
candidates. While at least 10 different scales have been published,40–49 the majority were 
derived from hospitalized AHF populations, from retrospective review of administrative 
data, or include data not available in most EDs. Accordingly, these scales have been 
designed to predict outcomes in AHF patients discharged from hospital wards, rather than 
directly from EDs. Despite being promising tools for outcome improvement, they ignore the 
16–36% of AHF patients already cared for in EDs that are entirely managed and directly 
discharged without hospital admission.
Currently, only two risk stratification scales have been created from ED cohorts, both 
derived in Canada. Stiell et al.40 developed the Ottawa Heart Failure Risk Scale from clinical 
data recorded in 559 patients diagnosed at six EDs. In the final model, the scale is based on 
10 clinical variables that rendered a moderate discriminative capacity in the derivation study 
(C-statistic of 0.77) and which remained practically unchanged by excluding results of 
natriuretic peptides (C-statistic: 0.75). On the other hand, Lee et al.41 developed the 
Emergency Heart Failure Mortality Risk Grade (EHMRG) derived from 7433 AHF cases 
(and validated in 5158) in 86 Canadian EDs. It estimates seven-day mortality risk in non-
palliative patients and is easily applicable as it is based on 10 ED relevant variables (and, 
optionally, the natriuretic peptide level) (Table 2). The EHMRG scale rendered a 0.807 and 
0.804 C-statistic for the derivation and validation cohorts, respectively. Validation in 
European cohorts is ongoing. The EHMRG is able to prospectively predict risk. In the 
lowest four deciles, seven-day mortality was 0.3%, as compared with 3.5% and 8.2% in 
deciles 9 and 10, respectively. Since an EHMRG calculator is available online (https://
ehmrg.ices.on.ca/#/), risk stratification is now quickly available. Additionally, as natriuretic 
peptides are not required in the EHMRG scale, it may be applied even in those EDs with 
laboratory limitations. However, as natriuretic peptides do have prognostic power,50,51 it will 
be important to determine their utility with such a tool in the future. It is important to note 
that the EHMRG scale is an informational tool designed to assist clinicians in the ED 
setting, and its use is not intended to replace clinical decision-making by a qualified medical 
professional. Future prospective studies evaluating its usefulness in a broader range of 
clinical settings are recommended.
Recent studies have demonstrated that measurement of global functional status (including 
comorbidities), aside from New York Heart Association class, contribute to better 
delineation of the risk of adverse outcomes, especially in the elderly.43,51 AHF in patients 
with advanced age may represent an important clinical entity potentially driven by different 
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mechanisms (e.g. greater rates of comorbidities and frailty) from in the young.51 Assessing 
these parameters at hospital admission, ideally in the ED, may improve management. In this 
regard, it has been suggested that the addition of Barthel Index measurements to the 
EFFECT scale (to create the BI-EFFECT scale) significantly improves prediction of 30-day 
mortality.43 Thus, appreciation of global functional status may be considered in future 
refinements of risk scales for AHF patient evaluation.
In the meantime, until a final validated risk stratification tool is available for emergency 
physicians, disposition decision-making will be guided by personal expertise and consensus 
documents. In this sense, the recent consensus attained among the Heart Failure Association 
of the European Society of Cardiology, the European Society of Emergency Medicine, and 
the Society of Academic Emergency Medicine about pre-hospital and early hospital 
management of AHF can assist in this setting.52 Based on this paper, we propose a general 
algorithm to be applied during the ED assessment of patients presenting with AHF (Figure 
2).
Role of biomarkers in risk stratification
The measurement of natriuretic peptides is extremely helpful in the ED diagnosis of AHF 
and can contribute to better patient management.50,51 ED use of natriuretic peptides 
significantly improves diagnostic accuracy,53,54 which has therapeutic and operational 
implications.55 It is less clear whether natriuretic peptide concentrations should also guide 
disposition decisions in the ED. In contrast to their determination at 48h, at hospital 
discharge, or in the stable outpatient setting, natriuretic peptide levels at ED presentation 
have low prognostic accuracy.56
Other biomarkers, like mid-regional pro-adrenomedullin, copeptin or procalcitonin, may 
also provide advice in diagnosis of undifferentiated ED patients with acute dyspnoea and 
might therefore be helpful to improve resource utilization and patient care.57–59 However, 
their utility in ED decision-making is not as well described as for the natriuretic peptides.
Role of ultrasonography
Echocardiography should be obtained at least once in every patient diagnosed with heart 
failure. This is because it helps establish the primary cause of the heart failure (especially for 
patients with the first episode), provides immediate information on chamber volumes, 
systolic and diastolic function, wall thickness and valve function, rules out potential 
complications and serves as a guide for therapeutic pathway determination.7 On the other 
hand, immediate complete echocardiography is not usually needed during the initial 
evaluation of most AHF diagnosed at ED, unless haemodynamic instability is present.52
One of the most important revolutions in EDs during the last decade has been the use of 
ultrasonography by emergency physicians. The integration of chest ultrasound into the 
emergency physician’s armamentarium has considerably changed the clinical diagnosis of 
pulmonary oedema. This is because the finding of echocardiographic B-lines is easily and 
reliably detected with just a few hours’ training, and enhances the diagnostic performance of 
the classical workup (based on chest X-ray) for AHF.60 A recent report has shown that, after 
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a 30-min chest ultrasonography course, emergency medicine residents can identify 
sonographic B-lines with accuracy similarly to an expert sonographer, which then allows a 
proper diagnosis of pulmonary oedema.61 The role of ED ultrasound for risk stratification in 
suspected AHF needs to be assessed in the near future.
Conclusions and future directions
We must provide the best patient care while balancing proper treatment and resource use. 
For those EDs having observation units, these settings seem an appropriate place to evaluate 
treatment response, as well as to arrange and ensure proper short term follow-up. With 
regard to the latter, disposition decision-making is fundamental. While not all patients with 
AHF require hospitalization, wrong discharge decisions may be associated with 
unacceptable risks of adverse outcomes. Participation of cardiologists, as well as heart 
failure teams where they exist, is highly recommended at this stage.
In selected candidates, when appropriate, direct ED discharge can be done with safety. 
Selection of appropriate candidates requires accurate risk stratification and becomes a key 
tool that can lead the decision-making process. However, risk stratification is not currently 
performed in most EDs, essentially because of the lack of proper and validated tools, and the 
absence of a clear definition of what a low risk means for AHF patients in terms of 
mortality, rehospitalization and ED re-consultation. All these issues have to be properly 
addressed by multidisciplinary research, involving cardiologists, internists, geriatricians and 
ED physicians, during the next coming years.13,62,63 In the meanwhile, we propose a 
consensus algorithm based on previous papers and on our own experience in order to be 
applied at EDs and to give some advice to emergency physicians treating AHF patients.
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Figure 1. 
Relationship between percentages of patients directly discharged from 25 Spanish 
emergency departments participating at the EAHFE Registry22 and outcomes.
AHF: acute heart failure; ED: emergency department
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Figure 2. 
General algorithm for disposition decision-making at emergency department for patients 
with acute heart failure.
*Risk stratification is highly recommended, and scales derived from patients attended at the 
emergency department (ED) (like Emergency Heart Failure Mortality Risk Grade or Ottawa 
Heart Failure Risk Scale) are preferred at this stage.40,41
**Intensive care unit (ICU) admission should be considered for patients classified as high 
risk by risk algorithms, and those with respiratory rate >25 beats/min, peripheral capillary 
oxygen saturation <90%, use of accessory muscles for breathing, systolic blood pressure<90 
mmHg, need of intubation or non-mechanical ventilation (or being already ventilated), need 
of invasive or continuous monitoring, need of intravenous vasodilators or inotropic support, 
signs of hypoperfusion: oliguria, cold peripheries, altered mental status, lactate >2 mmol/l, 
metabolic acidosis, mixed venous oxygen saturation <65% (partially based on the consensus 
document of Mebazaa et al.52).
***Direct ED discharge should be considered for patients with self-reported subjective 
improvement, resting heart rate <100 beats/min, no hypotension when standing, adequate 
urine output, oxygen saturation >95% in room air, no or moderate worsening of renal 
function (chronic renal disease might be present) (partially based on the consensus 
document of Mebazaa et al.52).
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Table 1
Some criteria that could be used, in conjunction with clinical judgment, to consider a patient with acute heart 
failure for discharge home directly from the emergency department.35
• Substantial subjective clinical improvement
• Respiratory rate <25/min
• Basal oxygen saturation > 90% (no home oxygen)
• Systolic blood pressure > 90 mmHg
• Resting heart rate < 100 beats/min
• Adequate diuresis (defined as >50 ml/h or >0.75 ml/kg per h; ideally, >1500 ml should be recorded during the first 24 h if patient 
remains in an observation unit)
• Controlled arrhythmia (atrial fibrillation with acceptable ventricular response)
• No chest pain
• Normal renal function (or moderate worsening of renal function, chronic renal disease might be present) and electrolytes
• If patients observed during 12–24 h, no increase in cardiac troponin
• Possibility of proper ambulatory follow-up
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Table 2
Variables included in the Emergency Heart Failure Mortality Risk Grade Model formulated by Lee et al.41 
Score calculation for a particular patient can be done through a web calculator (https://ehmrg.ices.on.ca/#/) 
which allocates patient in low (deciles 1 to 4), medium (deciles 5 to 7) or high (deciles 8 to 10) risk category.
Variablea Unit of measurement
Age Continuous in years
Transported by EMS Categorical
Systolic blood pressure Continuous in mmHg (max = 160 mmHg)
Heart rate Continuous in beats/min (min = 80, max = 120 beats/min)
Oxygen saturation Continuous as % (max = 92%)
Creatinine Continuous as mg/dl
Potassium Categorical:
4.0 to 4.5 mmol/l
≥ 4.6 mmol/l
≤ 3.9 mmol/l
Troponin Categorical
Active cancer Categorical
Metolazone at home Categorical
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